Jul. 23 (Reuters) - Summit Therapeutics Q2 EPS USD -0.28. * Q2 operating expenses USD 220.5 million
Back to newsSummit Therapeutics Q2 Net Income USD -215.7 MillionSSMMT•2026-07-23Q2 resultsJul. 23 (Reuters) - Summit Therapeutics Q2 EPS USD -0.28. Q2 operating expenses USD 220.5 million Related NewsSSleep Number Corp - Enters Amended And Restated Asset Purchase Agreement On July 18, 2026 - SEC FilingSNBR•2026-07-23BBaiya International Group May Offer Up To $200 Million In Securities - SEC FilingBIYA•2026-07-23AAdtran Strengthens Capital Structure With New Senior Secured Credit FacilityADTN•2026-07-23
SMMT•SMMT•SMMT•SMMT•
